SURF AIR MOBILITY INC. current report, 02 April 2024

Surf Air Mobility Inc. — Form 8-K Summary

Business Context and Reporting Period

The Form 8-K reports an NYSE continued-listing deficiency received by Surf Air Mobility Inc. on April 2, 2024. The company is incorporated in Delaware and trades under the symbol SRFM on the New York Stock Exchange.

Financial and Operating Metrics

The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial performance metrics.

Material Change and Listing Status

  • The NYSE notified the company that its common stock had an average closing price below $1.00 over 30 consecutive trading days, violating Section 802.01C of the NYSE Listed Company Manual.
  • The notice had no immediate effect on the listing of the company’s common stock.
  • The company must notify the NYSE within 10 business days of its intent to cure the deficiency and stated that it intends to do so.
  • The company has six months from receipt of the notice to regain compliance. Compliance may be regained if, on the last trading day of a calendar month during the cure period or on the last trading day of the cure period, the stock’s closing price and its 30-trading-day average closing price are each at least $1.00.

Outlook, Risks, and Unusual Items

Management stated that the notice is not expected to affect business operations or SEC reporting obligations. However, failure to regain compliance within the cure period could result in additional NYSE action, including potential delisting, although the filing does not state that delisting is currently pending.

The company issued a related press release on April 5, 2024, included as Exhibit 99.1. The filing was signed by Chief Financial Officer Oliver Reeves on April 5, 2024.

Key Facts for Investors to Verify

  • Whether the company timely notified the NYSE of its intent to cure the deficiency.
  • Whether the stock achieved both the required $1.00 closing price and 30-trading-day average closing price during the six-month cure period.
  • Any subsequent NYSE notices, extensions, reverse stock split actions, or delisting proceedings.
  • The company’s financial condition and liquidity, which are not addressed in this filing.